Description
p.Glu1325Ala (GAA>GCA): c.3974 A>C in exon 33 of the FBN1 gene (NM_000138.4) While the E1325A mutation in the FBN1 gene has not been reported to our knowledge, a mutation affecting this same residue, (E1325Q), has been reported in association with Marfan syndrome (Biggin A et al., 2004). Additionally, mutations in nearby residues (D1322H, D1322G, C1326R, C1333S ) have been reported in association with Marfan syndrome, further supporting the functional importance of this residue and this region of the protein. E1325A, within EGF - like calcium binding domain 22 of FBN1, results in a non- conservative amino acid substitution, which is likely to impact secondary protein structure as these residues differ in polarity, charge, size and/or other properties. The E1325 residue is highly conserved across species. In silico analysis predicts this variant is probably damaging to the protein structure/function. Furthermore, E1325A was not observed in approximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations. In summary, E1325A in the FBN1 gene is interpreted as a likely disease-causing mutation. The variant is found in TAAD panel(s).
# | Sample | Method | Observation |
---|
Origin | Affected | Number tested | Tissue | Purpose | Method | Individuals | Allele frequency | Families | Co-occurrences |
---|
1 | germline | yes | not provided | not provided | not provided | | not provided | not provided | not provided | not provided |